Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,417.54 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. ↗
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech. 
Via The Motley Fool
News headline image
Amneal (AMRX) Q3 earnings: what to expect
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what to expect. Amneal beat analys... 
Via StockStory
News headline image
What to expect from Pfizer’s (PFE) Q3 earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven... 
Via StockStory
News headline image
Corcept (CORT) to report earnings tomorrow: here is what to expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday after market hours. Here’s what to look for. Corcept be... 
Via StockStory
Topics Artificial Intelligence
Eli Lilly (NYSE:LLY) Beats Q3 Estimates, Raises Guidance as Shares Jump ↗
Via Chartmill
News headline image
Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts? ↗
Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing. 
Via MarketBeat
News headline image
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom? ↗
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point. 
Via The Motley Fool
News headline image
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be... 
Via StockStory
News headline image
After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock? ↗
Eli Lilly stock is trading at a record high. 
Via The Motley Fool
Topics Earnings
News headline image
Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030 ↗
GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly. 
Via The Motley Fool
News headline image
2 Stocks Billionaires Can't Stop Buying ↗
Should you buy these stocks, too? 
Via The Motley Fool
News headline image
What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call ↗
Eli Lilly and Company (NYSE:LLY) raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound... 
Via MarketBeat
Topics ETFs Earnings
News headline image
OmniAb (OABI) Q3 2026 Earnings Call Transcript ↗
Revenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones. 
Via The Motley Fool
Topics Earnings
News headline image
Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going? ↗
Eli Lilly's business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate. 
Via The Motley Fool
News headline image
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF ↗
VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Has Big Plans for 2030. Should You Buy the Stock Now? ↗
The company’s comeback strategy looks sound. 
Via The Motley Fool
News headline image
Eli Lilly (LLY) Q3 2026 Earnings Call Transcript ↗
Revenue surged 39% on blockbuster obesity drug demand and strong international growth. 
Via The Motley Fool
Topics Earnings
S&P 500 Top Movers: Oct. 29, 2026 Gainers and Losers ↗
Via Chartmill
Topics Stocks
News headline image
Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction ↗
Eli Lilly’s realized prices fell 15%, but a 53% jump in volume pushed revenue up 39% and lifted full-year guidance by $5.5 billion. Here’s why the math works, and what could break it. 
Via The Motley Fool
S&P 500 Top Movers: Today's US Session Gainers and Losers ↗
Via Chartmill
Topics Stocks
S&P 500 Gap Movers: October 29, 2026 Session ↗
Via Chartmill
Topics Stocks
News headline image
Eli Lilly (LLY) shares skyrocket, what you need to know
What happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 8.1% in the morning session after the company reported third-quarter 2026 ... 
Via StockStory
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments. 
From FN Media
Via GlobeNewswire
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance ↗
Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound. 
Via Investor's Business Daily
News headline image
Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 38.6% year on year to... 
Via StockStory
News headline image
Could Revolution Medicines Be a Millionaire-Maker Stock? ↗
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one. 
Via The Motley Fool
News headline image
Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test ↗
Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study. 
Via Investor's Business Daily
News headline image
Eli Lilly (LLY) reports earnings tomorrow: what to expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before market hours. Here’s what you need to know. Eli Lilly beat... 
Via StockStory
Topics Artificial Intelligence
News headline image
$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today ↗
The company has made longtime shareholders much richer. 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.